Overview

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Status:
RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
Phase:
PHASE1
Details
Lead Sponsor:
AbbVie